These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 35503375)
1. Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. Giannoccaro MP; Vacchiano V; Leone M; Camilli F; Zenesini C; Panzera I; Balboni A; Tappatà M; Borghi A; Salvi F; Lugaresi A; Rinaldi R; Di Felice G; Lodi V; Lazzarotto T; Liguori R; J Neurol; 2022 Aug; 269(8):4000-4012. PubMed ID: 35503375 [TBL] [Abstract][Full Text] [Related]
2. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145 [TBL] [Abstract][Full Text] [Related]
3. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A; EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223 [TBL] [Abstract][Full Text] [Related]
5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
6. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab. Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M Front Immunol; 2023; 14():1149629. PubMed ID: 37398654 [TBL] [Abstract][Full Text] [Related]
7. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines. Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K Front Immunol; 2023; 14():1081933. PubMed ID: 37545513 [TBL] [Abstract][Full Text] [Related]
8. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A; Front Immunol; 2022; 13():868915. PubMed ID: 35432335 [TBL] [Abstract][Full Text] [Related]
9. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
10. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364 [TBL] [Abstract][Full Text] [Related]
11. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K Front Immunol; 2021; 12():704773. PubMed ID: 34220867 [TBL] [Abstract][Full Text] [Related]
12. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A Front Immunol; 2022; 13():846248. PubMed ID: 35432314 [TBL] [Abstract][Full Text] [Related]
13. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232 [TBL] [Abstract][Full Text] [Related]
14. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
15. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
17. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289 [TBL] [Abstract][Full Text] [Related]
18. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002 [TBL] [Abstract][Full Text] [Related]
19. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose. Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073 [TBL] [Abstract][Full Text] [Related]
20. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]